4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxyquinazolin-2-amine hydrochloride

• ChemBase编号: 154910
• 分子式: C31H37ClN4O6
• 平均质量: 597.10168
• 单一同位素质量: 596.2401626
• SMILES: COc1ccc(cc1OC)CCNc1nc2cc(c(cc2c(n1)N1CCc2cc(c(cc2C1)OC)OC)OC)OC.Cl
• Canonical SMILES: COc1cc2nc(NCCc3ccc(c(c3)OC)OC)nc(c2cc1OC)N1CCc2c(C1)cc(c(c2)OC)OC.Cl
• InChI: InChI=1S/C31H36N4O6.ClH/c1-36-24-8-7-19(13-25(24)37-2)9-11-32-31-33-23-17-29(41-6)28(40-5)16-22(23)30(34-31)35-12-10-20-14-26(38-3)27(39-4)15-21(20)18-35;/h7-8,13-17H,9-12,18H2,1-6H3,(H,32,33,34);1H
• InChIKey: WWCHXVYTCMPAMV-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxyquinazolin-2-amine hydrochloride
• IUPAC传统名: 4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxyquinazolin-2-amine hydrochloride
• 别名: 4-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxy-2-quinazolinamine monohydrochloride; CP-100356 monohydrochloride; CP-100356 Hydrochloride

登记号

• CAS号: 142715-48-8
• MDL号: MFCD00911858
• PubChem SID: 162249048
• PubChem CID: 71312025

理论计算性质

• Acid pKa: 16.594355
• 质子受体: 10
• 质子供体: 1
• LogD (pH = 5.5): 3.6596088
• LogD (pH = 7.4): 4.918264
• Log P: 5.1105967
• 摩尔折射率: 159.7514 cm^3
• 极化性: 60.93138 Å^3
• 极化表面积: 96.43 Å^2
• 可自由旋转的化学键: 11
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: Chloroform; DMSO: >5 mg/mL; Methanol
• 外观: Off-White to Light Tan Solid; white to off-white powder
• 熔点: 210-212°C

安全信息

• 保存条件: Refrigerator
• 德国WGK号: 3
• 保存温度: 2-8°C

产品相关信息

• 纯度: >98% (HPLC)
• Empirical Formula (Hill Notation): C31H36N4O6 · HCl

详细说明

Sigma Aldrich - PZ0171

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
CP-100356 is a specific inhibitor of MDR1 (P-Gp), the protypical ABC transporter. The compound has low uM to nM potency for inhibiting several MDR-1 substrates (calcein-AM, digoxin) in transfected MDCKII cells. CP-100356 also inhibits prazosin transport in human breast cancer resistance protein (BCRP)-transfected MDCKII cells, suggesting that it acts as a dual inhibitor. CP-100356 does not inhibit multidrug resistance-associated protein 2 (MPR2 IC50 >15 mM).

Toronto Research Chemicals - C781250

CP-100356 is a specific inhibitor of MDR1 (P-Gp), the protypical ABC transporter. CP-100356 also inhibits prazosin transport in human breast cancer resistance protein (BCRP)-transfected MDCKII cells, suggesting that it acts as a dual inhibitor. CP-100356

参考文献

• Ayrton, A., et al.: Xenobiotica, 31, 469 (2001)
• Mizuno, N., et al.: Pharmacol. Rev., 55, 425 (2001)
• Fojo, T., et al.: Clin. Breast Cancer, 7, 749 (2001)
• Polli, J., et al.: Drug Metab. Dispos., 36, 695 92008),